|
CYTOCHROME P450 INHIBITORS MAY INHIBIT 25 HYDROXYLATION OF DOXERCALCIFEROL, HENCE FORMATION OF ACTIVE MOITY MAY BE HINDERED
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
EFAVIRENZ DECREASE PLASMA CONCENTRATION OF THE DRUG
|
EFAVIRENZ DECREASE PLASMA CONCENTRATION OF THE DRUG
|
EFAVIRENZ DECREASE PLASMA CONCENTRATION OF THE DRUG
|
CO-ADMINISTRATON PRODUCED A 22% INCREASE IN THE CMAX OF AZITHROMYCIN
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
CO-ADMINISTRATION CAN INCREASE PLASMA LEVELS OF CICLESONIDE LEADING TO INCREASED CHANCES OF CUSHING SYNDROME
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
EFAVIRENZ SHOULD NOT BE CO-ADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
EFAVIRENZ SHOULD NOT BE CO-ADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
EFAVIRENZ SHOULD NOT BE CO-ADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|